Dabogratinib (Onc)
Non-Muscle Invasive Bladder Cancer (NMIBC)
Key Facts
About Tyra Biosciences
Tyra Biosciences is focused on advancing a robust pipeline of selective FGFR inhibitors for oncology and genetically defined conditions. Its core technology platform enables rapid structure-based design to create molecules that address key limitations of current therapies, such as resistance mutations and off-target toxicity. With multiple clinical-stage assets, including dabogratinib in Phase 2 and TYRA-200/430 in Phase 1, the company is targeting significant markets in achondroplasia, bladder cancer, and cholangiocarcinoma.
View full company profileAbout Tyra Biosciences
Tyra Biosciences is focused on advancing a robust pipeline of selective FGFR inhibitors for oncology and genetically defined conditions. Its core technology platform enables rapid structure-based design to create molecules that address key limitations of current therapies, such as resistance mutations and off-target toxicity. With multiple clinical-stage assets, including dabogratinib in Phase 2 and TYRA-200/430 in Phase 1, the company is targeting significant markets in achondroplasia, bladder cancer, and cholangiocarcinoma.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NDV-01 | Relmada Therapeutics | Phase 2/3 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |